Justices Deny Norwich Challenge of Generic Xifaxan Injunction

The US Supreme Court won’t take up Norwich Pharmaceuticals Inc.’s request to review a district court’s judgment blocking its copies of Bausch Health Cos.’ Xifaxan until 2029.

The high court on Monday declined Norwich’s bid to review the Delaware federal court’s interpretation of the Hatch-Waxman Act of 1984. Norwich had argued the lower court ruling improperly delayed approval of a generic drug for a use that doesn’t infringe valid patents and urged the justices to “correct the lower court’s interpretation of the Act and thereby restore the balance that Congress put in place and that is vital to the Act’s ...